UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

SCHEDULE 14A
(RULE 14a-101)

INFORMATION REQUIRED IN PROXY STATEMENT

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. _____)

Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐

Check the appropriate box:

☐ Preliminary Proxy Statement

☐ **Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2))**

☐ Definitive Proxy Statement

☑ Definitive Additional Materials

☐ Soliciting Material Pursuant to § 240.14a-12

Nabi Biopharmaceuticals
(Name of Registrant as Specified in its Charter)

N/A
(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

Payment of Filing Fee (Check the appropriate box):

☑ No fee required.

☐ Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

(1) Title of each class of securities to which transaction applies:

(2) Aggregate number of securities to which transaction applies:

(3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

(4) Proposed maximum aggregate value of transaction:

(5) Total fee paid:

☐ Fee paid previously with preliminary materials.

☐ Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

(1) Amount Previously Paid:

(2) Form, Schedule or Registration Statement No.:

(3) Filing Party:

(4) Date Filed:

In connection with the proposed business combination transaction between Nabi Biopharmaceuticals (the "Company") and Biota Holdings Limited, the Company has filed a definitive proxy statement, dated August 7, 2012, with the Securities and Exchange Commission ("SEC") in connection with a special meeting of stockholders of the Company to be held on September 24, 2012.

STOCKHOLDERS AND INVESTORS ARE URGED TO READ THE COMPANY'S DEFINITIVE PROXY MATERIALS AND ANY OTHER RELEVANT SOLICITATION MATERIALS FILED BY THE COMPANY WITH THE SEC BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED BUSINESS COMBINATION TRANSACTION. Stockholders and investors may obtain a free copy of the Company's definitive proxy statement and other materials filed by the Company with the SEC at the SEC's website at www.sec.gov, at the Company's website at www.nabi.com, or by contacting Morrow & Co., LLC, the Company's proxy solicitation agent, at (203) 658-9400 or toll-free at (800) 607-0088.

The Company's board of directors has determined that it is advisable and in the best interests of the Company and its stockholders to consummate the proposed business combination transaction and unanimously recommends that you vote "FOR" each of the proposals to be considered and voted upon at the special meeting by signing and dating the WHITE proxy card or WHITE voting instruction form that you previously received.

On August 31, 2012, the Company provided the following presentation materials to Institutional Shareholder Services Inc.

NABI
BIOPHARMACEUTICALS

biota

BIOTA PHARMACEUTICALS INC.

Forward Looking Statement

This presentation contains forward looking statements that involve risks and uncertainties. Although we believe that the expectations reflected in the forward looking statements are reasonable at this time, Biota and Nabi can give no assurance that these expectations will prove to be correct. Actual results could differ materially from those anticipated. Reasons may include risks associated with drug development and manufacture, risks inherent in the regulatory processes, delays in clinical trials, risks associated with patent protection, future capital needs or other general risks or factors. We caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. We disclaim any obligation to publicly update or revise any such statements to reflect any change in its expectations or events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.

Relenza® is a registered trademark of GlaxoSmithKline. Inavir® is a registered trademark of Daiichi Sankyo.

Forward Looking Statements regarding the Proposed Nabi-Biota Transaction

This presentation also contains forward-looking statements about the occurrence, timing and financial terms or effect of the proposed merger between Nabi and Biota, including expected timing for closing, which are based on certain assumptions made by us based on current conditions, expected future developments and other factors we believe are appropriate in the circumstances. No assurances can be given, however, that these activities, events or developments will occur or that such results will be achieved. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of Nabi or Biota. Several of these risks associated with Nabi are outlined in Nabi's Definitive Proxy Statement filed with the Securities and Exchange Commission ("SEC") on August 7, 2012, and other documents Nabi files with the SEC. We caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. We disclaim any obligation to publicly update or revise any such statements to reflect any change in its expectations or events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.

Important Additional Information

In connection with the transaction, Nabi has filed a definitive proxy statement, dated August 7, 2012, with the SEC in connection with a special meeting of stockholders of Nabi to be held on September 24, 2012. STOCKHOLDERS AND INVESTORS ARE URGED TO READ NABI'S DEFINITIVE PROXY MATERIALS AND ANY OTHER RELEVANT SOLICITATION MATERIALS FILED BY NABI WITH THE SEC BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT THE TRANSACTION. Stockholders and investors may obtain a free copy of Nabi's definitive proxy statement and other materials filed by Nabi with the SEC at the SEC's website at www.sec.gov, at Nabi's website at www.nabi.com, or by contacting Morrow & Co., LLC, Nabi's proxy solicitation agent, at (203) 658-9400 or toll-free at (800) 607-0088.

NABI BIOPHARMACEUTICALS

biota

Merger Rationale

- Enables Nabi to transition into a revenue generating, late stage integrated biotechnology company
- Opportunity for Nabi's shareholders to participate in the likely growth of the merged company
- Result is a leading company in anti-infective drug discovery and development

NABI BIOPHARMACEUTICALS

biota

The Combined Company

	Biota Pharmaceuticals
Three royalty generating products	✓
$231m BARDA contract	✓
Attractive clinical and preclinical products	✓
$100m+ of cash	✓
Increased ability to fund future clinical programs	✓
Increased ability to manage Relenza patent cliff	✓

NABI BIOPHARMACEUTICALS

biota

Biota Pharmaceuticals - Pipeline



NABI BIOPHARMACEUTICALS

biota

Influenza Market

- **The market is divided into two distinct opportunities:**
  - Seasonal influenza market (prescription and pharmacy)
  - Stockpile market (governments)
- **Market is cyclical**

NABI BIOPHARMACEUTICALS

biota

Laninamivir
Second Generation Influenza Antiviral

- **Laninamivir octanoate is a pro-drug converted to laninamivir in the lung**
- **Marketed as Inavir® (Daiichi Sankyo) in Japan (approved October 2010)**
- **Single 40mgm dose for treatment, "one and done"**
  - Relenza 10mgm bd 5 days, Tamiflu 75mgm bd 5 days
- **Once weekly for prevention**
  - Relenza 10mgm daily, Tamiflu 15mgm daily
- **Disposable, IP protected inhaler**
- **Broad strain antiviral efficacy (4AH5N1,9AH1N1)**
  - Effective against Tamiflu resistant clinical isolates
- **Dosing advantage**
  - Reduced stockpile/distribution
  - Enhanced compliance

NABI BIOPHARMACEUTICALS

biota

Inavir® Dry Powder Inhaler

- **Marketed in Japan by Daiichi Sankyo with royalties to Biota**
  - Approximately 4-6% on sales
- **Registration supported in Japan by:**
  - Phase II/III pediatric (treatment) trial completed in 2009
  - Phase III trial in adults (treatment) completed in 2009
- **Phase III prophylaxis trial completed demonstrating efficacy. DS indicated that it will submit for prophylaxis license in 2012**
- **Laninamivir is co-owned with Daiichi Sankyo**
  - Daiichi Sankyo hold marketing rights in Japan
  - Biota is developing Laninamivir in the US (and other western markets) under a BARDA contract. Biota will hold
    - Approved US NDA
    - GMP approval
    - Manufacturing capacity to supply ROW



NABI BIOPHARMACEUTICALS

biota

BARDA Contract Overview with Biota

- **US$231M contract for advanced development of laninamivir to lead to US NDA within 5 years**
- **Major components of contract are**
  - Process development, scale-up, commissioning of US based manufacturing capability for laninamivir octanoate
  - Supply of clinical trial products
  - The completion of all relevant Phase I, Phase II and Phase III clinical studies for treatment
  - Preparation of NDA submission
- **Cost reimbursement, plus 7% fee**
- **No IP encumbrance**
- **No dilution to shareholders**

NABI BIOPHARMACEUTICALS

biota

Human Rhinovirus - BTA798 (vapendavir)

- **Oral small molecule inhibitor of human rhinovirus (HRV)**
  - Binds to capsid protein on surface of virus particle
  - Broad spectrum HRV antiviral
- **Target markets**
  - Serious complications in patients with asthma, COPD, Cystic Fibrosis
  - Patients with compromised immune systems (chemotherapy, transplants)
- **Phase IIa challenge study demonstrated proof-of-concept in humans; reducing incidence and severity of HRV infection**
- **Phase IIb trial in patients with chronic asthma met primary end point in March 2012**
- **Protected by patents owned by Biota**

NABI BIOPHARMACEUTICALS

biota

Respiratory Syncytial Virus (RSV)

- **For unserved infant and elderly markets**
  - U.S. mortality in the elderly estimated at 17,000 deaths per year
- **Potential RSV market for treatment and prophylaxis is large**
  - MedImmune (AZ) dominates prophylaxis market with Synagis® >$1bn
    - Synagis – mAb by injection and limited reimbursement scope
  - No treatment product available
- **New lead candidate identified**
  - RSV fusion inhibitor
- **Strong IP position**
  - Solely owned by Biota

NABI BIOPHARMACEUTICALS

biota

Hepatitis C Non Nucleoside (HCV-NN)

- Non-nucleoside NS5b inhibitor
- Nanomolar pan-genotypic
- Intended for Interferon free combination
- Active in HCV replicon
- Orally bioavailable
- IP owned by Biota

NABI BIOPHARMACEUTICALS

biota

Gyrase (GYR) Anti-bacterial

- GyrB/ParE inhibitor
- Equivalent or superior to Zyvox™ in multiple animal models
- IV/ Oral switch profile
- Effective against multidrug resistant bacteria in pre-clinical studies
- Low resistance frequency
- IP owned by Biota

NABI BIOPHARMACEUTICALS

biota

Opportunity Summary

- **If the merger is approved, Biota Pharmaceuticals, Inc. will have**
  - Three royalty generating products, Relenza, Inavir and potentially PhosLyra
  - Two clinical programs
    - Laninamivir (a long acting anti-influenza neuraminidase inhibitor) - US $231 million contract with BARDA for the advanced development,
    - Vapendavir (a phase III-ready human rhinovirus program)
  - NicVAX interest
  - Pre-clinical programs, including respiratory syncytial virus (RSV), hepatitis C (HCV-NN), broad spectrum antibiotic targeting gyrase (GYR)
  - Over US$100 million in cash with which to develop its program pipeline

NABI BIOPHARMACEUTICALS

biota

Key Aspects of Agreement

- Nabi will acquire all of the outstanding ordinary shares in Biota
- Nabi's post-merger assets contribution to the merged company includes $54 million in cash, a right to receive royalties from a marketed product (PhosLyra) and an interest in NicVAX vaccine
- Nabi plans to return to its stockholders its remaining cash in excess of the $54 million required to be held by Nabi at closing after satisfying outstanding liabilities
- Nabi intends to distribute contingent value right related to NicVAX to current Nabi shareholders
- Immediately following the closing of the merger, the board of directors of the combined company will consist of six current Biota Directors and two current Nabi Directors.

NABI BIOPHARMACEUTICALS

biota

Anticipated Merger Timeline

- Merger Agreement announced — 23 April
- Scheme Booklet/Proxy to Shareholders — August
- Meetings of Shareholders — September
- If transaction is approved, Biota Pharmaceuticals Inc. listed on Nasdaq — October

NABI BIOPHARMACEUTICALS

biota

Nabi's Assets as of Q2, 2012

- **Cash: $92.6 million at end of June, 2012**
- **Potential remaining NicVAX value: GSK's second generation asset and relapse prevention study in the Netherlands**
- **Potential PhosLyra royalties**
- **Net Operating losses (NOLs), value limited due to merger**

NABI BIOPHARMACEUTICALS

biota

Nabi's Cash Assets

- **Merger agreement obligates Nabi to provide $54 million in cash at close to the combined company**
- **Additionally, after satisfying its liabilities, Nabi indicated that it will distribute $25 million to $30 million to shareholders in the form of a dividend, a return of capital, a tender offer or a combination**
  - Nabi has already returned $24.4 million to its shareholders in the form of a Dutch Auction Tender Offer

NABI BIOPHARMACEUTICALS

biota

Tender Offer ..Background

- **Nabi has at least two major groups of shareholders:**
  - Traditional long term shareholders who are interested in participating in the growth of the combined company
  - Arbitrage shareholders who invested in the stock after the failure of NicVAX with the view to benefit from the arbitrage between the market cap and cash available
- **Clearly the investment thesis is completely different between the two groups**

NABI BIOPHARMACEUTICALS

biota

Tender Offer ..Strategy

- **Nabi implemented a Dutch Auction Tender Offer to allow arbitrage shareholders to exit the stock, while allowing traditional investors to participate in the potential benefits from the merger**

NABI BIOPHARMACEUTICALS

biota

Tender Offer ...Outcome

- **The Tender Offer was successful and over-subscribed**
  - A total of 14,547,996 shares were accepted for purchase, representing approximately 33.93% of the total outstanding shares, at a purchase price of $1.68 per share, a premium of approximately 5% over the Nabi trading share price

NABI BIOPHARMACEUTICALS

biota

Liquidation Scenario as an Alternative

- **Under the liquidation scenario, Nabi estimates that the amount of cash available to shareholders is as follows:**
  - $1.51 to $1.68 upon approval of liquidation (approximately three to four months after the Sept 24th vote)
  - Over the following three years, shareholders may receive additional distributions of the $5 million to $10 million reserve, provided that there are no legitimate claims on any of said reserve

NABI BIOPHARMACEUTICALS

biota

The Math..for Liquidation Scenario

- Nabi's cash at the end of Q2 = $92.6 million
- Tender offer plus expenses = ($24.7 million)
- Operating cost to October 2012 = ($1.5 million)
- Wind-down costs = ($13.6 million)
- Subtotal = $52.8 million
- Reserve = ($5 million) to ($10 million)
- At start of liquidation = $48 million to $43 million
- Shares outstanding = 28,328,034
- Initial distribution per share at start of liquidation = $1.51 to 1.68

NABI BIOPHARMACEUTICALS

biota

Alternative Proposed by some Shareholders

- **Distribute substantially all the cash then merge with another company for the public listing:**
  - This alternative is speculative under new Nasdaq rules and may not yield the desired outcome if Nabi is deemed a shell company
- **Distribute substantially all the cash then ask a third party liquidator to assume liability:**
  - We also believe that this alternative may be even more expensive to shareholders, because a third party liquidator would likely request the same reserve and to make a profit would incur a higher operating cost

Potential Benefits of US Capital Markets

- **Primary objective is to realize value of laninamivir in the US**
- **US is key**
  - BARDA contract is highly US focused
    - US manufacturing capacity
    - High US clinical component
    - US regulatory requirements
    - BARDA's location
  - Achieving success likely requires a significant US presence by Biota
  - On completion, major customer is US Government

NABI BIOPHARMACEUTICALS

biota

Summary

- **Nabi undertook a comprehensive strategic alternative process with the help of investment bankers and other advisors**
- **Through the process, a merger with Biota was identified as an advisable and recommended alternative to other opportunities (including liquidation)**
  - Commercial stage company with two royalty-bearing drugs
  - Lead compound being developed for the US and other western countries, is already licensed in Japan
  - Deep and attractive pipeline

NABI BIOPHARMACEUTICALS

biota